Japan:
A recent study (Doki et al., 2022) published in the New England Journal of Medicine revealed that treatment with
nivolumab plus chemotherapy or nivolumab plus ipilimumab results in
significantly longer overall survival than chemotherapy alone for patients with
previously untreated advanced esophageal squamous cell carcinoma (ESCC).
The
researchers conducted a phase 3 trial involving 970 patients with previously
untreated, unresectable advanced, recurring, or metastatic ESCC, randomized to
receive either nivolumab plus chemotherapy (321 patients), nivolumab plus the
monoclonal antibody ipilimumab (325 patients), or chemotherapy alone (324
patients).
About our services: http://www.worksure.org
#patientengagement #patientexperience #clinicaltrials #clinicaldevelopment #clinicalstudies #clinicaldevelopment
